Kuddo

Cover Block

PUBLIC

Field	Value
Name	Kuddo
Tagline	AI-driven platform for patient insights in therapy settings
Headquarters	San Francisco, United States
Business Model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Founding Team	Co-Founders (2)
Clinical Focus	Eating disorder treatment

Links

PUBLIC

• Website: https://kuddo.club/
• LinkedIn: https://www.linkedin.com/company/kuddohealth

Executive Summary

PUBLIC

Kuddo is an early-stage San Francisco healthtech company building an AI companion for clinicians, patients, and families navigating eating disorder treatment, with the stated goal of scaling treatment fidelity rather than just access [kuddo.club] [LinkedIn, 2026]. The company positions itself in a clinical category, evidence-based eating disorder care, where therapist supply is constrained and adherence to manualized protocols is known to vary widely between providers. This is the gap it appears to be addressing.

The product, as described on the company site, applies fine-tuned large language models to identify therapist behaviors, treatment phases, and protocol adherence, and offers continuous between-session support to families [kuddo.club]. Co-founder and CEO Wenyi Zhu, a Carnegie Mellon Tepper alumna, previously held roles at CyberConnect, Protocol Labs, Citi and CICC, a background that mixes crypto-era engineering organizations with traditional finance [LinkedIn] [rocketreach.co]. Chief Clinical Officer Anne Claire Grammer, PhD, is a licensed clinical psychologist whose public profile emphasizes AI applications in youth mental health and clinical training methodology [LinkedIn, 2026].

Funding, investors, and revenue are not publicly disclosed at the time of writing. This is consistent with a pre-seed or seed-stage profile but limits external validation. Over the next 12 to 18 months, the questions that will most shape Kuddo's trajectory are whether it can publish or cite a named clinical partner site, whether its fidelity-scoring claims survive peer review or third-party benchmarking, and whether it can attach to either a payer reimbursement pathway or an enterprise contract with a multi-site eating disorder provider.

Data Accuracy: YELLOW -- Founder, leadership, and product framing are corroborated across LinkedIn, the company site, and third-party data brokers; funding and traction are not independently confirmed.

Taxonomy Snapshot

Axis	Value
Business Model	B2B
Industry / Vertical	Healthtech, behavioral health
Technology Type	Fine-tuned LLMs
Geography	North America (HQ San Francisco)
Founding Team	Two co-founders, clinician plus operator

Company Overview

PUBLIC

Kuddo is a San Francisco-based healthtech startup focused on bringing machine learning to the delivery and supervision of eating disorder therapy. The company describes its mission in clinical, not consumer, terms: scaling the quality of treatment, not merely broadening access to it [LinkedIn, 2026]. That framing matters because eating disorders carry one of the highest mortality rates of any mental illness and rely heavily on manualized, evidence-based modalities such as Family-Based Treatment and CBT-E, where adherence to protocol is itself a clinical variable.

The founding date is not publicly disclosed, but third-party records suggest CEO Wenyi Zhu has been working full-time on Kuddo for roughly 18 months as of the most recent capture [SignalHire]. Zhu, the only publicly listed founder, is joined by Anne Claire Grammer, PhD, as Chief Clinical Officer. Grammer's LinkedIn profile flags expertise in AI applications to youth mental health and in clinical training methodology [LinkedIn, 2026] [zoominfo.com]. The company appears to operate under the kuddo.club consumer-facing domain and a kuddo.io operational domain referenced in third-party contact databases [zoominfo.com].

Key corporate milestones such as incorporation date, financing rounds, and named pilot sites are not publicly available. Investors evaluating the company should expect to source a cap table, formation documents, and any IRB or clinical partnership letters directly from the founders, since none are surfaced in public databases at the time of this report.

Data Accuracy: ORANGE -- Single-source or company-source for most claims; founder identity is the only fact corroborated across two independent surfaces.

Product and Technology

MIXED

Kuddo's public product description centers on three linked use cases inside eating disorder treatment programs. First, a clinician-facing layer that uses fine-tuned LLMs to identify therapist behaviors, treatment phases, and adherence to a given evidence-based protocol [PUBLIC] [kuddo.club]. Second, a safety layer designed to detect high-risk behaviors early so that clinical teams can intervene before a patient destabilizes [PUBLIC] [kuddo.club]. Third, a family support layer that provides continuous guidance to caregivers between sessions, an area that maps closely to Family-Based Treatment, the leading evidence-based modality for adolescent anorexia [PUBLIC] [kuddo.club].

The technical claim with the most strategic weight is the fidelity-scoring engine. The company asserts that benchmarking improves with each partner site, framing data accumulation as a moat that compounds over time [PUBLIC] [kuddo.club]. In behavioral health AI, that is a credible structural argument: fidelity models depend on labeled session transcripts, and labels are scarce, expensive, and clinically sensitive. If Kuddo can secure exclusive or semi-exclusive labeling relationships with eating disorder programs, the asymmetry between its dataset and a generalist competitor's grows with each engagement. The unverified question is whether such partnerships exist today; none are publicly named.

The underlying tech stack, model providers, hosting environment, and HIPAA posture are not described publicly. Given the clinical context, prospective enterprise buyers and investors will want documented BAAs, evidence of de-identification or on-premise deployment options, and clarity on whether fine-tuning occurs on customer data, on synthetic data, or on a research corpus.

Data Accuracy: ORANGE -- All product claims trace to the company's own site or LinkedIn; no independent technical validation, peer-reviewed publication, or customer reference is publicly available.

Market Research and Opportunity

PUBLIC

The market matters now because behavioral health AI has moved from chatbot novelty to clinically supervised infrastructure. Eating disorders sit at the intersection of high acuity, scarce specialists, and payer interest in measurement-based care.

The specialty eating disorder treatment market in the United States is served by a relatively small number of multi-site providers (Monte Nido, Equip, Eating Recovery Center, Center for Discovery, Alsana) plus a long tail of academic medical centers and outpatient practices. Demand pressure is well documented: published epidemiology in the post-2020 period showed sharp increases in adolescent eating disorder presentations, and waitlists at specialty programs have been a recurring theme in clinical and trade press. The supply constraint, fully trained clinicians in evidence-based modalities such as FBT and CBT-E, is structural rather than cyclical. This is precisely the gap that a fidelity-and-coaching layer is designed to address.

The adjacent and substitute markets are instructive. AI-assisted clinical documentation and supervision tools (notably Eleos Health and Lyssn in adjacent behavioral health categories) have built distribution by selling into community mental health and substance use providers. Their playbook is to start with documentation ROI and expand into fidelity and outcomes. Pure-consumer mental health apps occupy a different lane and generally do not address acute clinical risk. Telehealth-native eating disorder providers such as Equip Health have raised meaningful venture capital and could either become Kuddo customers or build comparable tooling in-house.

Regulatory and reimbursement forces cut both ways. The shift toward measurement-based care and value-based contracts in behavioral health rewards vendors who can quantify protocol adherence and outcomes. At the same time, FDA posture on clinical-decision-support software, evolving state-level AI-in-healthcare rules, and HIPAA enforcement raise the compliance bar for any tool that touches patient sessions. None of the public sources captured for this report quantify the eating-disorder-software TAM specifically, so a numeric market chart is omitted here in favor of the qualitative map above.

Data Accuracy: YELLOW -- Market structure and demand drivers reflect widely reported industry context; no Kuddo-specific market sizing is publicly available.

Competitive Landscape

MIXED

Kuddo is positioned in a narrow but strategically important slice of behavioral health AI: clinician-facing fidelity and family-facing continuity, scoped to a single high-acuity condition.

The closest analogues by category, drawn from widely reported coverage of behavioral health AI, fall into three groups. The first group is generalist therapy-AI infrastructure: companies such as Eleos Health and Lyssn that score therapist behaviors and adherence across a broad set of modalities, typically sold into community mental health, SUD, and group practices. The second group is condition-specific virtual providers, most notably Equip Health in eating disorders, which deliver care directly and could either buy a fidelity layer or build one. The third group is the in-house data science and quality teams at the large multi-site eating disorder providers themselves, which historically have built bespoke outcome dashboards and could extend into AI-assisted supervision.

Kuddo's defensible edge today, if the public product description holds up under diligence, is condition-specificity. A fidelity model trained on FBT and CBT-E session transcripts is not the same artifact as a generalist therapy-fidelity model, and clinical buyers in this category tend to value depth over breadth. The presence of a licensed clinical psychologist as Chief Clinical Officer is a credibility signal that pure-engineering teams in this category often lack [LinkedIn, 2026]. Whether that edge is durable depends almost entirely on whether Kuddo can lock in early data partnerships with named programs before a generalist competitor decides eating disorders are worth a vertical SKU.

The company's most concrete exposure is distribution. Generalist behavioral-health-AI vendors already have enterprise sales motions into integrated delivery networks and large group practices. Kuddo, as far as public information shows, does not yet have a comparable named-account footprint. There is also a channel Kuddo does not own, the EHR layer, which in eating disorder programs is fragmented but increasingly important for any tool that wants to ingest session data at scale.

The most plausible 18-month competitive scenario has two bookends. Kuddo wins if it signs an exclusive or semi-exclusive data and deployment partnership with one of the top five multi-site eating disorder providers in the United States. This would convert the dataset-moat thesis from a claim into a fact. Kuddo loses if a well-funded generalist therapy-AI vendor announces an eating-disorder vertical with a named clinical advisory board and an existing enterprise contract. In that case, Kuddo's window to establish category ownership narrows considerably.

Data Accuracy: ORANGE -- Competitive frame is constructed from publicly reported category context; no head-to-head benchmarks or named competitor mentions in Kuddo source material were captured.

Opportunity

PUBLIC

The size of the prize, if Kuddo executes, is becoming the default fidelity and continuity layer for evidence-based eating disorder care in the English-speaking world.

Eating disorders are one of the few mental health categories where clinical outcomes are tightly coupled to protocol adherence, where families are formal participants in treatment, and where the supply of trained specialists is structurally short of demand. A vendor that can credibly quantify therapist fidelity, surface high-risk patient signals between sessions, and keep families coached through the hardest moments of treatment is solving a problem that named clinical leaders in the field have been describing for two decades. The cited evidence that this outcome is reachable rather than aspirational is twofold: the company has a clinician of record in Anne Claire Grammer, PhD, whose stated focus is exactly the intersection of AI and youth mental health [LinkedIn, 2026], and the public product description is grounded in specific clinical constructs (therapist behaviors, treatment phases, adherence) rather than generic chatbot framing [kuddo.club].

Growth scenarios

Scenario	What happens	Catalyst	Why it's plausible
Anchor partner	Kuddo signs a flagship multi-site eating disorder provider as a fidelity and family-support layer across all programs	A named pilot converts to a paid enterprise contract with published outcome data	The category has a small number of large multi-site operators, so a single anchor changes Kuddo's reference profile materially [kuddo.club]
Payer wedge	A commercial payer or a value-based contract requires measurement-based care metrics that Kuddo's fidelity engine produces natively	Payer policy shift toward outcome-based reimbursement in behavioral health	Behavioral health is the most active category for value-based experimentation, and adherence-linked outcomes are the most defensible metric a vendor can offer
Family-side network	The family-facing coaching product becomes a recommended adjunct that providers prescribe alongside FBT, creating a second go-to-market motion	A clinical study or trade-press writeup attributing reduced caregiver burden or readmission to the tool	The company explicitly frames continuous family support as a core pillar [kuddo.club]

What compounding looks like. The flywheel Kuddo describes is dataset-driven: each partner site contributes labeled session data that improves the fidelity benchmark, which in turn makes the next site's pitch easier and the next clinician's supervision tighter [kuddo.club]. In behavioral health AI, that compounding is real but only if labeling rights are negotiated up front and if the vendor avoids the trap of bespoke per-customer models. A second compounding mechanism is clinical credibility: published outcomes or peer-reviewed validations in this category travel quickly through a small community of program directors and academic PIs, and one well-cited study can shorten the sales cycle for the next ten accounts.

The size of the win. No public TAM figure exists for the eating-disorder-software niche specifically, so the comparison has to be drawn from adjacent behavioral health AI peers. Eleos Health and Lyssn, the most cited generalist examples in trade coverage, have raised institutional capital on the thesis that therapy-fidelity AI is a venture-scale category. If Kuddo becomes the condition-specific standard for eating disorders the way certain oncology decision-support tools became standards in their specialties, the scenario outcome is a category-defining vertical AI company with enterprise contracts across the named multi-site providers and a defensible clinical dataset (scenario, not a forecast).

Data Accuracy: ORANGE -- Opportunity scenarios are analyst constructions grounded in the company's stated product framing and widely reported category context; no Kuddo-specific revenue, pipeline, or pilot data is publicly disclosed.

Sources

PUBLIC

1. [websets.exa.ai] Executive Leadership Team at Kudos: Driving Innovation in Employee Engagement | https://websets.exa.ai/websets/directory/kudos-executives

2. [SignalHire] Wenyi Zhu's email and phone number, Founder and CEO at KUDDO | https://www.signalhire.com/profiles/wenyi-zhu's-email/133208877

3. [LinkedIn] Wenyi Zhu, Founder at Kuddo | https://www.linkedin.com/in/wzhu81/

4. [kuddo.club] Kuddo company website | https://kuddo.club/

5. [LinkedIn] Kuddo company page | https://www.linkedin.com/company/kuddohealth

6. [LinkedIn] Carnegie Mellon Tepper School of Business post referencing Wenyi Zhu | https://www.linkedin.com/posts/carnegie-mellon-tepper-school-of-business_congratulations-to-tepper-acs-scholars-jay-activity-6753776105821364224-aItj

7. [LinkedIn, 2026] Anne Claire Grammer, PhD, Chief Clinical Officer at Kuddo | https://www.linkedin.com/in/agrammer/

8. [rocketreach.co] Wenyi Zhu, Kuddo Founder and CEO contact information | https://rocketreach.co/wenyi-zhu-email_77493328

9. [zoominfo.com] Wenyi Zhu, Founder and CEO at Kuddo | https://www.zoominfo.com/p/Wenyi-Zhu/10778929382

10. [zoominfo.com] Anne Grammer, Chief Clinical Officer at Kuddo | https://www.zoominfo.com/p/Anne-Grammer/3705382059